---
layout: default
title: Triamcinolone
parent: Model Prediction Only (L5)
nav_order: 854
evidence_level: L5
indication_count: 10
---

# Triamcinolone
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Triamcinolone: From Corticosteroid Anti-inflammatory Treatment to Idiopathic Steroid-Sensitive Nephrotic Syndrome

## One-Sentence Summary

Triamcinolone is a synthetic corticosteroid, with currently missing mechanism of action (MOA) data, but based on pharmacological classification it is widely used for inflammation, allergy, and autoimmune-related diseases; the drug is currently **Not marketed** in India, with no local drug approval. TxGNN has predicted a total of 10 candidate indications for this drug, among which **Idiopathic Steroid-Sensitive Nephrotic Syndrome** has the highest mechanistic plausibility and evidence quality (predicted score **99.76%**), currently supported by **3 publications**, but there are no triamcinolone-specific clinical trials. The remaining 9 candidates are mostly follicle/alopecia-related rare diseases with lower evidence quality (mostly L5, Hold).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indications | Data missing (Not marketed in India, no approved indication text; known to be used for inflammation/allergy/autoimmune diseases based on pharmacological classification) |
| Predicted New Indications | Idiopathic Steroid-Sensitive Nephrotic Syndrome |
| TxGNN Predicted Score | 99.76% (raw score 0.99758, rank 4783) |
| Evidence Level | L3 (observational research/systematic review) |
| India Market Status | ✗ Not marketed |
| Drug Approval Registration Count | 0 |
| Recommended Decision | Proceed with Guardrails (proceed with additional conditions) |

---

## Why Is This Prediction Reasonable?

Currently, there is no detailed mechanism of action (MOA) data for triamcinolone. Based on available information, triamcinolone is a corticosteroid drug with anti-inflammatory and immunosuppressive properties, which is the core pharmacological characteristic already widely verified for this class of drugs.

Idiopathic steroid-sensitive nephrotic syndrome is defined by **definition itself as "nephrotic syndrome responsive to corticosteroid therapy"**—in other words, corticosteroids (such as prednisolone) are already the standard first-line treatment for this disease. Triamcinolone, as a corticosteroid of the same class, has high mechanistic plausibility and consistency with this indication, which is why this candidate has the highest evidence level among the 10 predictions (L3) and received the "Proceed with Guardrails" recommendation.

It should be noted that all attached literature represents reviews of treatment strategies or case series, reflecting the established position of "corticosteroids as a drug class" in this disease, and lacks controlled trials specifically targeting triamcinolone's specific dosage form/dose, which is an area that needs to be strengthened in follow-up work.

---

## Clinical Trial Evidence

No related clinical trials registered at present

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|--------------|
| [20156172](https://pubmed.ncbi.nlm.nih.gov/20156172/) | 2010 | Review | Current Medicinal Chemistry | Review of treatment strategies for idiopathic nephrotic syndrome in children, with the majority of cases responding to steroid therapy; steroid-dependent cases require adjunctive therapy such as calcineurin inhibitors |
| [22495188](https://pubmed.ncbi.nlm.nih.gov/22495188/) | 2012 | Review | Minerva Pediatrica | Review of new treatment strategies for idiopathic nephrotic syndrome, with the majority of patients responding to steroids, emphasizing the central role of steroids in this disease |
| [4834775](https://pubmed.ncbi.nlm.nih.gov/4834775/) | 1974 | Retrospective Cohort | American Journal of Diseases of Children | Clinical reassessment case series of 148 children with idiopathic nephrotic syndrome |

---

## Other Candidate Indications (Lower Priority, for Reference)

In addition to the main candidate mentioned above, TxGNN predicted a total of 10 indications, most of which are follicle/alopecia-related rare diseases with lower evidence quality and are not recommended for priority resource allocation at this time:

| Rank | Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|------|-----------|-------------|-----------------|-----------------|-----------------|
| 1 | Alopecia mucinosa | 99.99% | pending | pending | Pending assessment (4 publications, all at case report level) |
| 2 | Telogen effluvium | 99.99% | L5 | S0 | Hold (not inflammation-driven pathophysiology, weak mechanistic association) |
| 3 | Quinquaud's folliculitis decalvans | 99.99% | L4 | S1 | Research Question (mechanistically plausible but literature does not directly correspond to triamcinolone) |
| 4 | Alopecia antibody deficiency | 99.99% | L5 | S0 | Hold (no literature/trial support) |
| 5 | Hereditary hypotrichosis with recurrent skin vesicles | 99.99% | L5 | S0 | Hold (single-gene disease, mechanistically unrelated) |
| 6 | Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | 99.99% | L5 | S0 | Hold (rare syndrome, no evidence) |
| 7 | Atrichia with papular lesions | 99.96% | L5 | S0 | Hold (abnormal keratin differentiation, not inflammation-driven) |
| 9 | Alopecia universalis onychodystrophy vitiligo | 99.75% | L5 | S0 | Hold (no literature/trial support) |
| 10 | Sporadic idiopathic steroid-**resistant** nephrotic syndrome | 99.74% | L5 | S0 | Hold (**mechanistic contradiction**: definition itself is lack of response to corticosteroids, which contradicts the mechanism of action of triamcinolone) |

---

## India Market Information

Triamcinolone is currently **Not marketed** in India, with no effective drug approvals registered, therefore no product name, formulation, or approved indication data is available for display.

---

## Safety Considerations

**Drug-Drug Interactions** (Source: DDI query, total of 696 interaction records; key excerpts listed below):

| Interacting Drug | Severity | Source |
|------------------|----------|--------|
| Adalimumab | Major | ddinter |
| Alefacept | Moderate | ddinter |
| Alemtuzumab | Moderate | ddinter |
| Aldesleukin | Moderate | ddinter |
| Zidovudine | Moderate | ddinter |
| Acetazolamide | Moderate | ddinter |
| Ibuprofen | Moderate | ddinter |
| Ketorolac | Moderate | ddinter |
| Isotretinoin | Moderate | ddinter |
| Salbutamol / Formoterol | Minor | ddinter |

Among these, the interaction with Adalimumab is classified as **Major** severity, and caution is warranted when both are used together regarding cumulative immunosuppression risk; interactions with other immunomodulators (Alefacept, Alemtuzumab, Aldesleukin) and NSAIDs (Ibuprofen, Ketorolac) are also recommended for clinical monitoring.

> Package insert warnings and contraindication data are currently missing (see Next Steps below, this is a Blocking-level data gap), preventing completion of S1 safety initial assessment; please refer to official package insert.

---

## Conclusions and Next Steps

**Decision: Proceed with Guardrails (proceed with additional conditions)**

**Rationale:**

The candidate indication of idiopathic steroid-sensitive nephrotic syndrome has high mechanistic plausibility (the disease definition itself is steroid responsiveness), and is supported by L3-level observational research/review literature, but currently lacks triamcinolone-specific controlled trials, and the drug is still Not marketed in India with missing package insert safety data, therefore it is not appropriate to directly determine Go, and needs to proceed with additional conditions.

**To continue moving forward, the following gaps must be addressed:**

- Obtain complete package insert warnings and contraindication data (DG001, Blocking level, necessary prerequisite for S1 safety initial assessment)
- Obtain complete mechanism of action (MOA) data for triamcinolone (DG002)
- Assess India market launch/introduction pathway (current market status is Not marketed, drug approval count is 0)
- Search for or plan prospective efficacy data specific to triamcinolone for idiopathic steroid-sensitive nephrotic syndrome to strengthen L3-level evidence
- The remaining 9 candidate indications (mostly L5/S0/Hold) are not recommended for resource allocation at this time, unless new literature or trial evidence emerges in the future; particular attention should be paid to rank 10 (steroid-resistant nephrotic syndrome) which is a mechanistic contradiction case and should not be confused with rank 8

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

